Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 273 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: methylphenidate (MPH) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Testing Methylphenidate for Smoking Abstinence

NCT00549640
View directory record Official record
Conditions
Smoking
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 3 Interventional

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy

NCT00485550
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 3 Interventional Results available

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00499863
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate transdermal system, Placebo
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
13 Years to 17 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

NCT01202734
View directory record Official record
Conditions
Healthy
Interventions
Methylphenidate HCl
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
20 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Nov 3, 2026, 9:34 PM EST
Not listed Phase 3 Interventional

A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV

NCT01599975
View directory record Official record
Conditions
HIV Dementia
Interventions
Long acting methylphenidate, Matched placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 2 Interventional

Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3

NCT00015054
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions

NCT00829673
View directory record Official record
Conditions
Healthy
Interventions
Dexmethylphenidate Hydrochloride
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 4 Interventional Results available

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT00429273
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine, Methylphenidate (MPH)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Impulsivity and Stimulant Administration

NCT01978431
View directory record Official record
Conditions
Cocaine Dependence, Impulsivity
Interventions
cocaine hydrochloride, methylphenidate
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Nov 3, 2026, 9:34 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Belsomra, Placebo, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 3, 2026, 9:34 PM EST
Not listed Phase 4 Interventional

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

NCT02677519
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Nov 3, 2026, 9:34 PM EST
Terminated Phase 3 Interventional

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

NCT06431256
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
4 Years to 5 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 3 Interventional

Methylphenidate in Treating Patients With Melanoma

NCT00003266
View directory record Official record
Conditions
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methylphenidate hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
57
States / cities
Scottsdale, Arizona • Palo Alto, California • Stanford, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Nov 3, 2026, 9:34 PM EST
Terminated No phase listed Observational

Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics

NCT00247689
View directory record Official record
Conditions
Substance Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Nov 3, 2026, 9:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Understanding Sleep Problems in Children With Autism Spectrum Disorder

NCT00691080
View directory record Official record
Conditions
Sleep Problems
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years to 9 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 2 Interventional

Psychostimulants for Fatigue in Prostate Cancer

NCT00138138
View directory record Official record
Conditions
Fatigue, Prostate Cancer
Interventions
Ritalin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

NCT04449250
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Dexmethylphenidate
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Nov 3, 2026, 9:34 PM EST
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Nov 3, 2026, 9:34 PM EST
Completed Not applicable Interventional Results available

Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)

NCT01740206
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine and/or methylphenidate, Hold stimulant medication
Drug · Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 4 Interventional

Concerta Treatment in Adults With ADHD NOS

NCT00181740
View directory record Official record
Conditions
ADHD NOS
Interventions
atomoxetine (Strattera)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2010 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 3 Interventional

Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)

NCT01411280
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
methylphenidate
Drug
Lead sponsor
Temple University
Other
Eligibility
6 Years to 16 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Nov 3, 2026, 9:34 PM EST
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Nov 3, 2026, 9:34 PM EST
Completed Phase 4 Interventional Results available

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

NCT02255565
View directory record Official record
Conditions
ADHD, Autism
Interventions
Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
5 Years to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Nov 3, 2026, 9:34 PM EST